Pantoprazole
Pantoprazole is a prescription medication used to treat conditions caused by excess stomach acid, such as gastroesophageal reflux disease (GERD) and peptic ulcers.
Indexed studies have shown that pantoprazole effectively reduces stomach acid production by inhibiting the proton pump in stomach cells. It has been compared with other proton pump inhibitors like omeprazole and rabeprazole, revealing similar efficacy but different absorption rates influenced by food intake. In patients with GERD, pantoprazole was found to be as effective as other proton pump inhibitors in maintaining intragastric pH levels, which helps manage symptoms of acid reflux.
Pantoprazole is also used in combination therapies for eradicating Helicobacter pylori infections that can cause ulcers. A potential side effect noted from cohort studies is headache, although the evidence strength for this connection is moderate.
While pantoprazole is generally effective and well-studied, the quality of evidence varies across different conditions and populations.
Sources
- Pantoprazole. (PMID:11402494)
- Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. (PMID:32711578)
- Pantoprazole: a proton pump inhibitor. (PMID:19938880)
- Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. (PMID:27782887)
- Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. (PMID:15095858)
- Pantoprazole: a new proton pump inhibitor. (PMID:11117653)
_Worker-drafted node, Hermes writer enrichment, pending editorial review._
Connections
Pantoprazole is a side effect of
Sources
- Pantoprazole. (2001) pubmed
- Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole. (2020) pubmed
- Pantoprazole: a proton pump inhibitor. (2009) pubmed
- Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. (2016) pubmed
- Pantoprazole based therapies in Helicobacter pylori eradication: a systematic review and meta-analysis. (2004) pubmed
- Pantoprazole: a new proton pump inhibitor. (2000) pubmed
- Pantoprazole-induced thrombocytopenia. (2006) pubmed
- Pantoprazole in Patients in the ICU. (2019) pubmed
- Pantoprazole: from drug metabolism to clinical relevance. (2008) pubmed
- Pantoprazole-induced Stevens-Johnson Syndrome: A Case-report. (2024) pubmed